EQUITY | NOTE 16 – EQUITY Authorized Capital On October 27, 2020, the shareholders approved to amend the Company’s articles of incorporation to increase the number of authorized shares of common stock from 14,285,714 25,000,000 0.0001 25,000,000 0.0001 On October 7, 2021, the shareholders approved to amend the Company’s articles of incorporation to increase the number of authorized shares of common stock from 25,000,000 50,000,000 0.0001 50,000,000 0.0001 Stock Option and Stock Issuance Plan 2019 Plan The Company’s board of directors and shareholders approved and adopted on October 28, 2019 the 2019 Equity Incentive Plan (“2019 Plan”), effective on October 28, 2019 under which stock options and restricted stock may be granted to officers, directors, employees and consultants in the form of non-qualified stock options, incentive stock-options, , stock appreciation rights, restricted stock awards, restricted stock Units, stock bonus awards, performance compensation awards (including cash bonus awards) or any combination of the foregoing. Under the 2019 Plan, the Company reserved 214,286 188,527 2020 Plan The Company’s board of directors and shareholders approved and adopted on October 27, 2020 the 2020 Equity Incentive Plan (“2020 Plan”), effective on October 27, 2020 under which stock options and restricted stock may be granted to officers, directors, employees and consultants in the form of non-qualified stock options, incentive stock-options, stock appreciation rights, restricted stock awards, restricted stock Units, stock bonus awards, performance compensation awards (including cash bonus awards) or any combination of the foregoing. Under the 2020 Plan, the Company reserved 1,750,000 889,756 2021 Plan The Company’s board of directors and shareholders approved and adopted on October 7,2021 the 2021 Equity Incentive Plan (“2021 Plan”), effective on September 16, 2020 under which stock options and restricted stock may be granted to officers, directors, employees and consultants in the form of non-qualified stock options, incentive stock-options, stock appreciation rights, restricted stock awards, restricted stock Units, stock bonus awards, performance compensation awards (including cash bonus awards) or any combination of the foregoing. Under the 2021 Plan, the Company reserved 1,500,000 471,348 MUSCLE MAKER, INC. & SUBSIDIARIES Notes to Consolidated Financial Statements NOTE 16 – EQUITY, continued Common Stock Issuances On February 17, 2020 the Company authorized the issuance of an aggregate of 25,616 On March 31, 2020, the Company issued 75,000 On April 21, 2020, the Company issued an aggregate of 51,105 357,735 On June 1, 2020, the Company issued 5,000 10,150 On June 5, 2020, the Company issued 15,000 46,050 On June 24, 2020 the Company authorized the issuance of an aggregate of 4,340 On August 21, 2020, the Company issued an aggregate of 53,571 200,705 On November 5, 2020, the Company issued 53,763 100,000 On November 30, 2020, the Company issued 82,500 176,138 On February 3, 2021, the Company issued an aggregate of 20,000 42,600 On April 30, 2021, the Company issued an aggregate of 10,000 14,700 On May 6, 2021, the Company issued an aggregate of 150,000 214,500 127,500 On May 27, 2021, the Company cancelled 11,879 11,879 On August 24, 2021, the Company issued an aggregate of 15,000 20,999 On August 26, 2021, the Company issued an aggregate of 1,100 1,540 MUSCLE MAKER, INC. & SUBSIDIARIES Notes to Consolidated Financial Statements NOTE 16 – EQUITY, continued Common Stock Issuances, continued On October 11, 2021, the Company issued an aggregate of 40,000 40,800 On October 22, 2021, the Company issued an aggregate of 15,000 15,150 On December 3, 2021, the Company issued 82,500 84,975 On December 7, 2021, the Company issued an aggregate of 160,000 177,600 On December 27, 2021, the Company issued 10,000 7,400 See Note 3 – Acquisitions – Pokemoto Acquisition and SuperFit Foods Acquisition for details related to the stock issuance in connection with the acquisitions. See Note 14 – Commitments and Contingencies – Consulting Agreements and Board Compensation for details related to additional stock issuances during the year ended December 31, 2021. See Note 15 – Equity – warrants, Closing of Offerings and Private placement for details related to various stock issuances. Closing of Offerings On February 12, 2020, the Company priced its initial public offering of 1,540,000 5.00 6,780,000 920,000 123,200 On September 10, 2020, the Company priced its public offering (“September Offering”) of 3,294,118 1.70 4,940,001 660,000 263,529 494,177 764,399 75,600 494,177 MUSCLE MAKER, INC. & SUBSIDIARIES Notes to Consolidated Financial Statements NOTE 16 – EQUITY, continued Private Placements On April 7, 2021, the Company entered into a Securities Purchase Agreement with an accredited investor (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) pursuant to which the investor agreed to purchase from the Company for an aggregate purchase price of approximately $ 10,000,000 1,250,000 4,115,227 2,865,227 2.43 2.42 0.01 2.43 5.5 The Securities Purchase Agreement contains customary representations, warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties thereto. Pursuant to the Securities Purchase Agreement, the Company was required to register the resale of the Shares and the shares issuable upon exercise of the Common Warrant and the Pre-Funded Warrant. The Company prepared and filed a registration statement with the Securities and Exchange Commission within 30 days of the date of the Securities Purchase Agreement and to used commercially reasonable efforts to have the registration statement declared effective within 90 days of the closing of the Private Placement. Pursuant to a placement agency agreement, dated April 6, 2021, between the Company and A.G.P./Alliance Global Partners (the “Placement Agent”) entered into in connection with the Private Offering, the Placement Agent acted as the sole placement agent for the Private Placement and the Company has paid customary placement fees to the Placement Agent, including a cash fee equal to 8 4 2.916 On November 17, 2021, the Company entered into a Securities Purchase Agreement with accredited investors (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) pursuant to which the investors (the “Purchasers”) agreed to purchase from the Company for an aggregate purchase price of approximately $ 15,000,000 6,772,000 0.0001 10,830,305 4,058,305 1.385 1.3849 0.0001 1.385 5 MUSCLE MAKER, INC. & SUBSIDIARIES Notes to Consolidated Financial Statements NOTE 16 – EQUITY, continued Private Placements, continued The Securities Purchase Agreement contains customary representations, warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties thereto. Pursuant to the Securities Purchase Agreement, the Company is required to register the resale of the Shares and the shares issuable upon exercise of the Common Warrant and the Pre-Funded Warrant. The Company was required to prepare and file a registration statement with the Securities and Exchange Commission within 30 days of the date of the Securities Purchase Agreement and used commercially reasonable efforts to have the registration statement declared effective within 90 days of the closing of the Private Placement. Pursuant to a placement agency agreement, dated November 17, 2021, between the Company and A.G.P./Alliance Global Partners (the “Placement Agent”) entered into in connection with the Private Offering, the Placement Agent acted as the sole placement agent for the Private Placement and the Company has paid customary placement fees to the Placement Agent, including a cash fee equal to 8 4 1.662 Warrant and Option Valuation The Company has computed the fair value of warrants granted and options accrued for as accrued compensation expense using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees is the contractual life. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected term of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. The options accrued for in accrued compensation expense had a grant date fair value of $ 46,000 14,000 66.77 112.17 0.12 0.23 0.34 1 0 1.42 2.71 MUSCLE MAKER, INC. & SUBSIDIARIES Notes to Consolidated Financial Statements NOTE 16 – EQUITY, continued Restricted Common Stock On February 18, 2020, the Company issued an aggregate of 216,783 1,083,915 agreements as part of completing the initial public offering. On August 11, 2020, the executive team entered into an agreement individually with the Company to cancel an aggregate of 216,783 1,083,893 1,200 On February 11, 2021, the Company issued an aggregate of 221,783 At December 31, 2021, there was no restricted common stock outstanding. A summary of the activity related to the restricted common stock for the years ended December 31, 2021 and 2020, respectively, is presented below: SCHEDULE OF ACTIVITY RELATED TO RESTRICTED COMMON STOCK Weighted Average Grant Total Date Fair Value Outstanding at January 1, 2020 2,426 65.33 Granted 216,783 5.00 Forfeited - - Vested (218,009 ) 5.34 Outstanding at December 31, 2020 1,200 65.33 Granted 221,783 2.87 Forfeited - - Vested (222,983 ) 3.21 Outstanding at December 31, 2021 - $ - MUSCLE MAKER, INC. & SUBSIDIARIES Notes to Consolidated Financial Statements NOTE 16 – EQUITY, continued Options On November 27, 2020, the Company issued an aggregate of 300,000 118,000 A summary of option activity during the years ended December 31, 2021 and 2020 is presented below: SCHEDULE OF OPTION ACTIVITY Weighted Weighted Average Average Remaining Number of Exercise Life Options Price In Years Outstanding, January 1, 2020 33,750 $ 9.33 0.60 Issued 300,000 3.33 Exercised - - Forfeited (33,750 ) 9.33 Outstanding, December 31, 2020 300,000 $ 3.33 1.10 Issued - - Exercised - - Forfeited (200,000 ) 2.50 Outstanding, December 31, 2021 100,000 $ 5.00 1.92 Exercisable, December 31, 2021 100,000 $ 5.00 1.92 The Company has estimated the fair value of the options using the Black-Scholes model using the following assumptions: SCHEDULE OF STOCK OPTIONS ASSUMPTIONS For the Year Ended December 31, 2020 Risk free interest rate 0.10 0.23 % Expected term (years) 0.34 5.00 Expected volatility 66.77 112.17 % Expected dividends 0.00 % Warrants See Note 16 – Equity – Private Placements for details related to the warrants issued during the year ended December 31, 2021. On May 24, 2021, the Company issued 1,465,227 14,652 MUSCLE MAKER, INC. & SUBSIDIARIES Notes to Consolidated Financial Statements NOTE 16 – EQUITY, continued Warrants, continued On May 28, 2021, the Company issued 1,400,000 14,000 On December 23, 2021, the Company issued 1,210,110 A summary of warrants activity during the years ended December 31, 2021 and 2020 is presented below: SCHEDULE OF WARRANTS ACTIVITY Weighted Weighted Average Average Remaining Number of Exercise Life Warrants Price In Years Outstanding, January 1, 2020 2,450,287 $ 5.51 3.7 Issued 486,729 3.65 Exercised (354,159 ) 6.74 Outstanding, December 31, 2020 2,582,857 $ 4.08 3.3 Issued 21,869,064 0.46 Exercised (4,075,337 ) 0.01 Forfeited (92,568 ) 19.99 Outstanding, December 31, 2021 20,284,016 $ 1.66 4.0 Exercisable, December 31, 2021 20,284,016 $ 1.66 4.0 The grant date fair value of warrants granted during the years ended December 31, 2021 was established during the Private Placement. The grant date fair value of warrants granted during the year ended December 31, 2020 was determined on the date of issuance using the Black-Scholes option pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company calculates the expected volatility using the historical volatility of comparable companies over the most recent period equal to the expected term and evaluates the extent to which available information indicates that future volatility may differ from historical volatility. The expected dividend rate is zero as the Company does not expect to pay or declare any cash dividends on common stock. The risk-free rates for the expected terms of the stock warrants are based on the U.S. Treasury yield curve in effect at the time of the grant. The Company has not experienced significant exercise activity on warrants. Due to the lack of historical information, the Company determined the expected term of its warrant awards issued using the simplified method. In applying the Black-Scholes option pricing model, the Company used the following assumptions: SCHEDULE OF WARRANTS ASSUMPTIONS For the Year Ended December 31, 2020 Risk free interest rate 1.37 % Expected term (years) 3.00 Expected volatility 55.33 % Expected dividends 0.00 % MUSCLE MAKER, INC. & SUBSIDIARIES Notes to Consolidated Financial Statements NOTE 16 – EQUITY, continued Stock-Based Compensation Expense Stock-based compensation related to restricted stock issued to employees, directors and consultants, warrants and warrants to consultants amounted to $ 2,207,046 2,806,336 2,200,274 2,803,716 6,772 2,620 |